Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3860625 | 0.74 | CNR1 (0.30) | CNR1 | |
| SCHEMBL860388 | 0.74 | CNR1 (0.30) | CNR1 | |
| SCHEMBL18527308 | 0.74 | CNR1 (0.30) | CNR1 | |
| SCHEMBL19008983 | 0.74 | CNR1 (0.33) | CNR1 | |
| SCHEMBL14908941 | 0.73 | CYP2A6 (0.41) | CNR1 | |
| SCHEMBL1671736 | 0.72 | — | — | |
| SCHEMBL3580246 | 0.70 | GRM5 (0.41) | — | |
| SCHEMBL4559390 | 0.69 | TYR (0.36) | CNR1 | |
| SCHEMBL18300454 | 0.69 | CNR1 (0.43) | CNR1 | |
| SCHEMBL19650143 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619402-A1 | GPR17 MODULATORS AND USES THEREOF | Myrobalan Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | CURIS INC (US) | 2025-07-17 | — | — | US | disclosed |
| CN-119613396-A | Pyrrolo-heterocyclic-3-sulfonamide compounds and their use in the preparation of inhibitors of the GPR17 receptor | 迈巴制药(南京)有限公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2024188287-A1 | BRM INHIBITOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 贝达药业股份有限公司 | 2024-09-19 | — | — | WO | disclosed |
| US-20240299385-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | REWIND THERAPEUTICS NV (BE) | 2024-09-12 | — | — | US | disclosed |
| WO-2024104462-A1 | GPR17 MODULATORS AND USES THEREOF | MYROBALAN THERAPEUTICS NANJING CO. LTD (CN) | 2024-05-23 | — | — | WO | disclosed |
| EP-4347558-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | ReWind Therapeutics NV (BE) | 2024-04-10 | — | — | EP | disclosed |
| CN-117794898-A | 3-pyrrolylsulfonamide compounds as GPR17 antagonists | 瑞文德医疗公众有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-116568686-A | Substituted pyrrolo [2,3-b ] pyridine and pyrazolo [3,4-b ] pyridine derivatives as protein kinase inhibitors | 重庆复尚源创医药技术有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-5472933-A | Plant growth regulators | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-12-05 | — | — | US | disclosed |
| WO-1995022545-A1 | 2-HETEROARYL-5,11-DIHYDRO-6H-DIPYRIDO[3,2-b:2',3'-e][1,4]DIAZEPINES AND THEIR USE IN THE PREVENTION OR TREATMENT OF HIV INFECTION | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1995-08-24 | — | — | WO | disclosed |
| EP-0656359-A1 | Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts and compositionsand methods of use thereof | STERLING WINTHROP INC. (US) | 1995-06-07 | — | — | EP | disclosed |
| EP-0647641-A1 | Substituted heterocyclylisoquinolinium salts and compositions and methods of usethereof | STERLING WINTHROP INC. (US) | 1995-04-12 | — | — | EP | disclosed |
| US-5356862-A | Herbicidal sulfonylureas | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-10-18 | — | — | US | disclosed |
| EP-0544705-A1 | DERIVATIVES OF MUPIROCIN | Beecham Group p.l.c. (GB) | 1993-06-09 | — | — | EP | disclosed |
| EP-0511993-A1 | HERBICIDAL SULFONYLUREAS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-11-11 | — | — | EP | disclosed |
| WO-1992004319-A1 | HERBICIDAL PYRROLESULFONYLUREAS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-03-19 | — | — | WO | disclosed |
| WO-1992002518-A1 | DERIVATIVES OF MUPIROCIN | BEECHAM GROUP PLC (GB) | 1992-02-20 | — | — | WO | disclosed |
| WO-1991010668-A1 | HERBICIDAL SULFONYLUREAS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | BAZ2A, BAZ2B, PI4KB | CNR1 4779/4885 |
| US-20240299385-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | GPR3, GPR27, GPR65 | CNR1 29/4885 |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | CNR1 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.